Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12857/115854
Title: Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss)
Authors: Ferrari, Stefano
Meazza, Cristina
Palmerini, Emanuela
Tamburini, Angela
Fagioli, Franca
Cozza, Raffaele
Ferraresi, Virginia
Bisogno, Gianni 
Mascarin, Maurizio
Cefalo, Graziella
Manfrini, Marco 
Capanna, Rodolfo
Biagini, Roberto
Donati, Davide
Picci, Piero
Keywords: Methotrexate;Neoadjuvant chemotherapy;Osteosarcoma;Tumor necrosis
Mesh headings: Antineoplastic Combined Chemotherapy Protocols;Bone Neoplasms;Neoadjuvant Therapy;Osteosarcoma
Secondary Mesh headings: Adolescent;Adult;Chemotherapy, Adjuvant;Child;Cisplatin;Disease-Free Survival;Doxorubicin;Drug Administration Schedule;Female;Follow-Up Studies;Humans;Ifosfamide;Italy;Male;Methotrexate;Prospective Studies;Randomized Controlled Trials as Topic;Survival Analysis;Treatment Outcome;Young Adult
Issue Date: 2014
Journal: Tumori 
Abstract: 
Based on the results of the ISG/OS-1 study, the MAP regimen (methotrexate [MTX], doxorubicin [ADM] and cisplatin [CDP] with the addition of ifosfamide [IFO] in poor-responder patients) was investigated in patients with nonmetastatic osteosarcoma of the extremity (ISG/OS-Oss study).
URI: http://hdl.handle.net/20.500.12857/115854
ISSN: 03008916
DOI: 10.1700/1778.19262
Appears in Collections:Articles

Show full item record

PubMed Central
Citations 50

8
Last Week
0
Last month
0
checked on Dec 6, 2021

SCOPUSTM   
Citations 5

13
checked on Aug 31, 2020

WEB OF SCIENCETM
Citations

16
checked on Dec 6, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.